ISSUES OF OPTIMIZATION OF METHOTREXATE THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS
Objective: to evaluate the safety and efficiency of monotherapy with methotrexate (MTX) solution for subcutaneous injection (SC MTX), by using the estimated dosing, in patients with rheumatoid arthritis (RA).Subjects and methods. A 12-month prospective controlled study enrolled 106 patients with ear...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2017-03-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/2337 |
| _version_ | 1826556020144472064 |
|---|---|
| author | G. I. Gridneva Yu. V. Muravyev E. L. Luchikhina N. V. Demidova D. E. Karateev |
| author_facet | G. I. Gridneva Yu. V. Muravyev E. L. Luchikhina N. V. Demidova D. E. Karateev |
| author_sort | G. I. Gridneva |
| collection | DOAJ |
| description | Objective: to evaluate the safety and efficiency of monotherapy with methotrexate (MTX) solution for subcutaneous injection (SC MTX), by using the estimated dosing, in patients with rheumatoid arthritis (RA).Subjects and methods. A 12-month prospective controlled study enrolled 106 patients with early RA who were given SC MTX was conducted at the V.A. Nasonova Research Institute of Rheumatology in the framework of the REMARCA (Russian invEstigation of MethotrexAte and biologicals for eaRly aCtive Arthritis) program.Results and discussion. 12-month SC MTX monotherapy could achieve the treatment goal (remission or low disease activity) in 68% of the patients with active RA who did not need biological agents (BAs). In 36% of the patients, the treatment caused adverse reactions (ARs) that were the basis for its complete discontinuation in 8%. The therapeutic effect of SC MTX depended on body mass index (BMI) and was more pronounced in patients with its normal values (≤25 kg/m2) than in those with overweight or obesity. The incidence of ARs did not depend on the duration of the disease and the weight of a patient receiving SC MTX. Addition of BAs to SC MTX monotherapy did not lead to an increase in the frequency of ARs. In early RA, the effect was better when SC MTX was used in combination with lowdose oral glucocorticoids. The findings showed the expediency of intensively using SC MTX at the doses calculated per 1 m2 of the body surface, the dependence of therapeutic action and the independence of the frequency and severity of ARs from the patient’s BMI. |
| first_indexed | 2024-04-09T22:24:16Z |
| format | Article |
| id | doaj.art-8532ce448f1548248293bcf54d34cb7d |
| institution | Directory Open Access Journal |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| last_indexed | 2025-03-14T08:06:03Z |
| publishDate | 2017-03-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj.art-8532ce448f1548248293bcf54d34cb7d2025-03-02T13:23:43ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922017-03-01551414710.14412/1995-4484-2017-41-472198ISSUES OF OPTIMIZATION OF METHOTREXATE THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITISG. I. Gridneva0Yu. V. Muravyev1E. L. Luchikhina2N. V. Demidova3D. E. Karateev4V.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyObjective: to evaluate the safety and efficiency of monotherapy with methotrexate (MTX) solution for subcutaneous injection (SC MTX), by using the estimated dosing, in patients with rheumatoid arthritis (RA).Subjects and methods. A 12-month prospective controlled study enrolled 106 patients with early RA who were given SC MTX was conducted at the V.A. Nasonova Research Institute of Rheumatology in the framework of the REMARCA (Russian invEstigation of MethotrexAte and biologicals for eaRly aCtive Arthritis) program.Results and discussion. 12-month SC MTX monotherapy could achieve the treatment goal (remission or low disease activity) in 68% of the patients with active RA who did not need biological agents (BAs). In 36% of the patients, the treatment caused adverse reactions (ARs) that were the basis for its complete discontinuation in 8%. The therapeutic effect of SC MTX depended on body mass index (BMI) and was more pronounced in patients with its normal values (≤25 kg/m2) than in those with overweight or obesity. The incidence of ARs did not depend on the duration of the disease and the weight of a patient receiving SC MTX. Addition of BAs to SC MTX monotherapy did not lead to an increase in the frequency of ARs. In early RA, the effect was better when SC MTX was used in combination with lowdose oral glucocorticoids. The findings showed the expediency of intensively using SC MTX at the doses calculated per 1 m2 of the body surface, the dependence of therapeutic action and the independence of the frequency and severity of ARs from the patient’s BMI.https://rsp.mediar-press.net/rsp/article/view/2337methotrexateoptimizationrheumatoid arthritisbody mass indexremarca. |
| spellingShingle | G. I. Gridneva Yu. V. Muravyev E. L. Luchikhina N. V. Demidova D. E. Karateev ISSUES OF OPTIMIZATION OF METHOTREXATE THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS Научно-практическая ревматология methotrexate optimization rheumatoid arthritis body mass index remarca. |
| title | ISSUES OF OPTIMIZATION OF METHOTREXATE THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS |
| title_full | ISSUES OF OPTIMIZATION OF METHOTREXATE THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS |
| title_fullStr | ISSUES OF OPTIMIZATION OF METHOTREXATE THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS |
| title_full_unstemmed | ISSUES OF OPTIMIZATION OF METHOTREXATE THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS |
| title_short | ISSUES OF OPTIMIZATION OF METHOTREXATE THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS |
| title_sort | issues of optimization of methotrexate therapy in patients with rheumatoid arthritis |
| topic | methotrexate optimization rheumatoid arthritis body mass index remarca. |
| url | https://rsp.mediar-press.net/rsp/article/view/2337 |
| work_keys_str_mv | AT gigridneva issuesofoptimizationofmethotrexatetherapyinpatientswithrheumatoidarthritis AT yuvmuravyev issuesofoptimizationofmethotrexatetherapyinpatientswithrheumatoidarthritis AT elluchikhina issuesofoptimizationofmethotrexatetherapyinpatientswithrheumatoidarthritis AT nvdemidova issuesofoptimizationofmethotrexatetherapyinpatientswithrheumatoidarthritis AT dekarateev issuesofoptimizationofmethotrexatetherapyinpatientswithrheumatoidarthritis |